Novel targeted therapies in lymphoid neoplasia: from apoptosis activation to microenvironment harnessing
Speaker: Patricia Pérez Galán
IDIBAPS- Hospital Clinic, Barcelona
Salón de actos del Centro de Investigación del Cáncer
In the last years it has been acknowledge that the origin of most of lymphoid neoplasia derives from a tight collaboration between specific genetic alterations and the support of the accompanying non-tumor cells, the so- called tumor microenvironment. A potentially effective treatment must attack tumor cells with targeted therapies and, at the same time, dismantle the 'contact network' that protects it, that is, the microenvironment. In this seminar we will discuss the evolution of targeted therapy in the context of several models of lymphoid neoplasia, including Mantle cell lymphoma, Chronic Lymphocytic Leukemia and Follicular Lymphoma, with special emphasis on apoptosis activators (Bcl2-inhibitors), kinase inhibitors (PI3K and BTK) and novel immunotherapies in in vitro and in vivo models of these entities.